This is an excellent study employing advanced single-cell multiomics to uncover the clonal evolution dynamics and drug response profiles in CK-AML. Your integration of structural variant data with transcriptomic and proteomic insights is highly commendable. I am particularly intrigued by the subclone-specific drug sensitivity findings and the identification of seismic amplifications in CK-AML.
Given the potential translational impact of your work, I wonder if you could expand on the practical clinical applications of your findings. For instance, how do you envision integrating subclone-specific drug response profiles into routine clinical workflows for CK-AML management? Additionally, could you comment on the scalability of the single-cell techniques you employed, particularly in resource-constrained settings, and the potential for cross-laboratory standardization of these methods?
Your insights on these points would be a valuable contribution to our discussion on advancing personalized treatment approaches in hematologic malignancies.